Source-grounded facts extracted from DAVITA INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
DAVITA INC. reported the quarter ended March 31, 2026 results: revenue $3.416 billion, net income $198 million, EPS $2.87.
“strong financial performance, and this quarter is no exception.” Financial and operating highlights for the quarter and year ended March 31, 2026: • Consolidated revenues were $3.416 billion. • Operating income was $482 million. • Diluted earnings per share from continuing operations was $2.87. • Operating cash flow was $321 million and free cash flow was $140”
DAVITA INC. amended credit facility with Wells Fargo Bank, National Association at Applicable Margin for the Tranche B-2 Term Facility is 175 basis points in the c.
“a repricing of the Company’s existing senior secured term loan “B” facility maturing in May 2031”
DAVITA INC. incurred term loan of $250 million with Wells Fargo Bank, National Association at Term SOFR plus 175 basis points maturing May 2031.
“incremental borrowing of Tranche B-2 Term Loans in an aggregate principal amount of $250 million”
Michael D. Staffieri changed role as Chief Operating Officer Emeritus at DAVITA INC..
“Mr. Maughan will replace Michael D. Staffieri, who will transition to the role of Chief Operating Officer Emeritus, as of the Effective Date.”
David P. Maughan was appointed as Chief Operating Officer, DaVita Kidney Care at DAVITA INC..
“David P. Maughan, Senior Vice President of the Company, has been appointed Chief Operating Officer, DaVita Kidney Care, effective September 15, 2024”
DAVITA INC. amended term loan of $1,640,250,847.08 with Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender at Term SOFR plus 200 basis points or Base Rate plus 100 basis points maturing May 2031.
“The Fourth Amendment, among other things, provides for an extension of the maturity date of a portion of the Company’s existing secured term loan B facility (the “Existing Tranche B-1 Term Facility”), from August 2026 to May 2031, in an aggregate principal amount of $1,640,250,847.08 (such extended portion, the “Extended Tranche B-1 Term Facility”).”
DAVITA INC. amended Fourth Amendment with Wells Fargo Bank, National Association valued at $1,640,250,847.08 (effective 2024-05-09).
“On May 9, 2024, DaVita Inc. (the “Company”) entered into a Fourth Amendment (the “Fourth Amendment”) to that certain Credit Agreement dated as of August 12, 2019”
DAVITA INC. reported for the quarter ended March 31, 2024 results: revenue $3.071 billion, net income $240, EPS $2.65.
“deliver clinical excellence,” said Javier Rodriguez, CEO of DaVita Inc. Financial and operating highlights for the quarter ended March 31, 2024: • Consolidated revenues were $3.071 billion. • Operating income was $484 million and adjusted operating income was $463 million. • Diluted earnings per share was $2.65 and adjusted diluted earnings per share was $2.38. •”
DAVITA INC. entered into Share Repurchase Agreement with Berkshire Hathaway Inc. valued at share repurchase agreement: Company to repurchase from Investor shares sufficient to return benefici (effective 2024-04-30).
“On April 30, 2024, DaVita Inc. (the “Company”) entered into a letter agreement (the “Share Repurchase Agreement”) with Berkshire Hathaway Inc., on behalf of itself and its Affiliates (as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended) (collectively, “Investor”), the largest stockholder of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.